Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid REMS Should Go Further And Focus On Drug Diversion, Consultants Say

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA public meeting features presentations of how track and trace technology can help prevent abuse of pain killers.

You may also be interested in...



As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class

In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.

As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class

In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.

REMS For Opioids Still Has A Long Road Ahead; Advisory Committee Is Likely

A finalized Risk Evaluation and Mitigation Strategy for opioids is a long way off - possibly more than a year - and FDA expects additional stakeholder and industry meetings, as well as a multidisciplinary advisory committee to take place before a program is set in stone

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel